Drug Trial Radar · NCT07899073
A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
Conditions
- Erectile Dysfunction
Interventions
HIP2602 + HPP2602-2Drug
Test drug
HPP2602-1 + HPP2602-2Drug
Control drug
HGP1201 + HPP2602-1Drug
Active Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of IIEF-EF domain score from baseline after 12 weeksTime frame: baseline, 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pusan National University Hospital
Busan, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.